Talphera, Inc.

TLPH Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.

1.08 0.01 +0.93%
Market cap
$55.5M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
n/a
Altman Z
−20.73
Beneish M
n/a
Dividend safety
n/a

Talphera, Inc. (TLPH) P/E ratio

Alert me on P/E ratio

Talphera, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.2× (August 2022) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2023 0.0× —
FY2022 0.3× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —
FY2015 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2025 0.0× —
Mar 2025 0.0× —
Dec 2023 0.0× —
Sep 2023 0.0× —
33 more quarters

Against its own ten years

Low 0.0× High 1.2×
Ten-year median 0.0×
Current reading's percentile 92

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on TLPH